Literature DB >> 24275520

Sensitivity testing of the Seizure Severity Questionnaire (SSQ).

Simon Borghs1, Christine de la Loge2, Yves Brabant3, Joyce Cramer4.   

Abstract

The sensitivity of the Seizure Severity Questionnaire (SSQ) was evaluated using pooled data from open-label extensions of two clinical trials in patients with partial-onset seizures. The SSQ includes questions relating to frequency and helpfulness of warning signs as well as frequency, severity, and bothersomeness of ictal and postictal effects. Differences between mean change from baseline for each SSQ item for responders and nonresponders were described and compared between patients solely with complex partial seizures (CPSs: responders, n=166; nonresponders, n=127) and those solely with secondarily generalized partial seizures (SGPSs: responders, n=26; nonresponders, n=24) at baseline. Seizure Severity Questionnaire total score and individual SSQ items related to ictal movement, consciousness, bothersomeness of postictal effects, and frequency of postictal emotional effects showed differentiation between seizure type responders. These data provide further validation of the SSQ by demonstrating its sensitivity in describing treatment effects.
© 2013.

Entities:  

Keywords:  Epilepsy; Patient-reported outcome; Seizure Severity Questionnaire (SSQ); Seizure severity; Sensitivity

Mesh:

Substances:

Year:  2013        PMID: 24275520     DOI: 10.1016/j.yebeh.2013.10.010

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  2 in total

1.  Understanding the Patient Perspective of Seizure Severity in Epilepsy: Development of a Conceptual Model.

Authors:  Simon Borghs; Erin L Tomaszewski; Katarina Halling; Christine de la Loge
Journal:  Patient       Date:  2016-10       Impact factor: 3.883

2.  Developing a Conceptual Disease Model of Patient Experiences and Identifying Patient-Reported Clinical Outcome Assessments for Use in Trials of Treatments for Focal Onset Seizures.

Authors:  Dorothee Oberdhan; Elizabeth Bacci; Jennifer N Hill; Andrew Palsgrove; Asha Hareendran
Journal:  Neuropsychiatr Dis Treat       Date:  2022-03-22       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.